Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience (SKYE) is a clinical-stage biopharmaceutical innovator developing targeted therapies through cannabinoid receptor modulation. This page serves as the definitive source for verified company announcements, research milestones, and financial updates.
Investors and researchers will find timely updates on clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes earnings reports, pipeline progress for nimacimab (peripheral CB1 inhibitor), and scientific presentations - all organized for efficient due diligence.
Key focus areas include metabolic disorder therapeutics, antibody-based drug development, and clinical safety data. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining accessibility for both specialist and general audiences.
Bookmark this page for structured access to SKYE's evolving position in biopharmaceutical innovation, with particular emphasis on obesity treatment research and peripheral endocannabinoid system modulation.
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech firm, will present at the Jefferies Global Healthcare Conference in NYC from June 5-6, 2024. CEO and Chair Punit Dhillon will outline the company's progress in obesity and glaucoma treatments on June 5 at 5:00 p.m. ET. A webcast of the presentation will be available.
Skye Bioscience presented new data at the ARVO 2024 Annual Meeting showcasing a novel library of synthetic cannabinoids for ocular diseases. The study focused on dry eye disease and chronic ocular pain, identifying three potential therapeutic candidates with innovative mechanisms of action. Skye aims to develop drugs modulating the endocannabinoid system to treat diverse ocular pathologies.
Skye Bioscience, Inc. (Nasdaq: SKYE) will present two posters at the ARVO 2024 Annual Meeting focusing on their Phase 1 study of a novel ocular drug and the development of synthetic endocannabinoid agonists. The event will take place in Seattle, Washington from May 5-9, 2024.